The University of Chicago Medicine Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 27 Trials 
40 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nanda, Rita
NCT02788981: Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Active, not recruiting
2
29
US
Mifepristone, KORLYM(R), Placebo, Nab-Paclitaxel, Abraxane®
University of Chicago
Breast Cancer
12/22
08/26
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
Saci-IO TNBC, NCT04468061: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Hourglass Jan 2022 - Jun 2022 : Initiation of P3 trial in combination with keytruda for 1L mTNBC
Recruiting
2
110
US
Sacituzumab Govitecan, IMMU-132, Trodelvy, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Gilead Sciences, Merck Sharp & Dohme LLC
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
04/26
04/29
NCT03941730: Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
5
US
Biopsy, BIOPSY_TYPE, Bx, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
Mayo Clinic, National Cancer Institute (NCI)
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
07/26
07/26
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
Saci-IO HR+, NCT04448886: Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC

Hourglass Jan 2021 - Jan 2021 : Data from trial for HR+ / HER2 – metastatic breast cancer
Active, not recruiting
2
110
US
Pembrolizumab, Keytruda, Sacituzumab Govitecan, TRODELVY
Ana C Garrido-Castro, MD, Merck Sharp & Dohme LLC, Gilead Sciences
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
03/24
06/27
NCT03225547: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Active, not recruiting
2
74
US
Pembrolizumab, Keytruda, Mifepristone, Mifeprex
University of Chicago
Triple Negative Breast Neoplasms, Breast Cancer
09/25
09/25
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
TBCRC 050, NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Recruiting
1/2
40
US
Niraparib, formerly MK-4827, Trastuzumab
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Tesaro, Inc., Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation of Alabama, VFoundation
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
11/24
12/24
NCT04942054: A Study in Patients With Advanced Breast Cancer

Terminated
1
9
US, RoW
Part 1, Part 2, Part 3
Sun Pharma Advanced Research Company Limited
HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
02/23
02/23
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
54
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/26
12/27
AURORA US, NCT03737695: Clinical Information and Biospecimen Collection from Patients with Recurrent or Stage IV Breast Cancer

Suspended
N/A
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Medical Chart Review, Chart Review
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC V8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
09/25
11/27
Chen, Nan
NCT05243199: Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

Completed
4
330
RoW
Sacubitril/Valsartan, ARNI, Irbesartan, ARB
Ruijin Hospital
CKD5 Stage Dialysis, Heart Failure
03/23
03/23
RITA, NCT04525729: Rituximab and RASi in Patients With IgAN

Recruiting
4
116
RoW
Rituximab, HLX01, RAS 2410, No specific restrictions
CHENNAN, Dongfang Hospital Affiliated to Tongji University, Shanghai Pudong New Area People's Hospital, Ruijin Hospital North Shanghai Jiao Tong University School of Medicine, Ningbo Municipal Yinzhou District No.2 Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Xiamen Hongai Hospital, Sir Run Run Shaw Hospital
IgA Nephropathy
07/23
12/23
NCT03448549: SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Recruiting
3
1191
RoW
Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda, Capecitabine
Peking University Cancer Hospital & Institute, Peking Union Medical College Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University People's Hospital
Colorectal Cancer Stage III, Adjuvant Chemotherapy
01/21
01/24
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
RCT, NCT04749381: The Role of TCM on ERAS of Rectal Cancer Patients

Recruiting
2
264
RoW
acupoint with TCM, acupoint with placebo
Beijing Cancer Hospital
Rectal Cancer
12/22
02/23
NCT04859621: Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections

Recruiting
2
150
RoW
Vitamin D3 4000 IU, Vitamin D3 2000 IU, Placebo, standard antibiotic therapy
Zensun Sci. & Tech. Co., Ltd.
Recurrent Urinary Tract Infection
04/25
07/25
PALAVY, NCT04841148: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Recruiting
2
96
US
HCQ, Hydroxychloroquine sulfate, Plaquenil, Avelumab, MSB0010718C, Bavencio, Palbociclib, Ibrance
Abramson Cancer Center at Penn Medicine, Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Breast Cancer
11/24
05/28
NCT06647940: Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

Recruiting
2
39
RoW
Orelabrutinib Oral Tablet, Bruton's Tyrosine Kinase Inhibitor, R-CHOP Protocol, R-CHOP regimen
Sun Yat-sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, Gansu Cancer Hospital, First Affiliated Hospital of Shantou University Medical College, Southern Medical University, China, Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shenzhen People's Hospital, Guangzhou First People's Hospital, Dongguan People's Hospital, The First People's Hospital of Zhaoqing
Diffuse Large B Cell Lymphoma (DLBCL)
11/26
03/27
NCT06114329: Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry Disease

Recruiting
2
16
RoW
AL01211
AceLink Therapeutics, Inc., Tigermed Consulting Co., Ltd
Fabry Disease
12/24
06/26
NCT06760039: Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

Not yet recruiting
1/2
112
RoW
R-CMOP Regimen, R-CHOP Regimen
Sun Yat-sen University
Diffuse Large B-Cell Lymphoma
08/28
11/28
STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
1
30
US
PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand
University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research
HER2-negative Breast Cancer, Metastatic Breast Cancer
04/25
04/25
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
54
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/26
12/27
TESTING-ON, NCT05434325: TESTING -ON Post-Trial ObservatioNal Cohort Study

Recruiting
N/A
366
Canada, RoW
The George Institute, Peking University Institute of Nephrology
IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases
07/27
07/27
Pohlmann, Paula
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
NCT05177796: Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn
2
30
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Panitumumab, ABX-EGF, ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, E7.6.3, Human IgG2K Monoclonal Antibody, MoAb ABX-EGF, MoAb E7.6.3, Monoclonal Antibody ABX-EGF, Monoclonal Antibody E7.6.3, Vectibix, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
07/23
07/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
TBCRC 044, NCT03095352: Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease

Completed
2
70
US
Pembrolizumab, Carboplatin, Ribocarbo, Trastuzumab
Hope Rugo, MD, Mayo Clinic, Johns Hopkins University, Translational Breast Cancer Research Consortium, Massachusetts General Hospital, Merck Sharp & Dohme LLC
Breast Cancer, Chest Wall Disease
11/24
11/24
NCT04602117: ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Withdrawn
1
27
US
Vic-trastuzumab duocarmazine (SYD985) + paclitaxel, SYD985, paclitaxel, SYD-985, Taxol, [vic-] trastuzumab duocarmazine
QuantumLeap Healthcare Collaborative, Byondis B.V.
HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985, Vic-trastuzumab Duocarmazine, Metastatic Cancer, Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic, HER2 Low Breast Cancer, GastroEsophageal Cancer, Gastroesophageal Adenocarcinoma, Endometrium Tumor, Ovarian Cancer, Ovarian Carcinoma, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2 Low HR Positive, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Bladder Cancer
11/21
11/21
NCT05511844: Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors

Active, not recruiting
1
87
US
ORM-5029
Orum Therapeutics USA, Inc.
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
04/25
10/25
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
54
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/26
12/27
Waldheim, Lindsey M
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
54
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/26
12/27

Download Options